Cationic lipids and transfection methods

US12344572B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12344572-B2
Application numberUS-202016920556-A
CountryUS
Kind codeB2
Filing dateJul 3, 2020
Priority dateJul 3, 2019
Publication dateJul 1, 2025
Grant dateJul 1, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of Formula (V) wherein R 21 , R 23 , and R 24 are independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxyalkyl, C 5-10 aryl, 5- to 10-membered heteroaryl, or C 3-6 cycloalkyl; n is an integer from 1 to 20; m is 6, 7, 8, 9, or 10; p is 1, 2, 3, or 4; q is 1, 2, 3, 4, or 5; and r is 1, 2, 3, 4, 5, or 6. 2. The compound of claim 1 , wherein R 21 , R 23 , and R 24 are hydrogen. 3. The compound of claim 1 , wherein n is 16, 17, 18, 19, or 20. 4. The compound of claim 3 , wherein: q is 4; p is 1; and r is 1. 5. The compound of claim 3 , wherein m is 8. 6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient. 7. A lipid aggregate comprising a compound of claim 1 . 8. The lipid aggregate of claim 7 , wherein the lipid aggregate does not comprise one or more additional lipids or polymers. 9. The lipid aggregate of claim 7 further comprising a nucleic acid, selected from a DNA molecule or an RNA molecule. 10. The compound of claim 1 , wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. 11. The compound of claim 1 , wherein n is 4.

Assignees

Inventors

Classifications

  • Dispersions; Emulsions · CPC title

  • Intradermal administration, e.g. through microneedle arrays or needleless injectors · CPC title

  • A61K47/543Primary

    Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine · CPC title

  • Compounds having three or more nucleosides or nucleotides · CPC title

  • comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543}) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12344572B2 cover?
The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.
Who is the assignee on this patent?
Factor Bioscience Inc
What technology area does this patent fall under?
Primary CPC classification A61K47/543. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).